Monday, May 12, 2008

Revance Takes $8M In Third Round

Mountain View-based Revance Therapeutics, which is developing biopharmaceuticals for the aesthetic medicine area, said Monday that it has raised an additional $8M In its Series C financing. According to the firm, the expansion was led by Bio*One Capital. other investors included Essex Woodlands Healthcare Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Medicis Pharmaceutical Corporation, Bio*One Capital and Pac-Link Ventures. The additional capital brings its Series C to $51.2M. Revance is developing a technique for non-invasive transcutaneous delivery of botulinum toxin (botox). More information »